Cullinan Therapeutics, Inc.

Cullinan Therapeutics, Inc.

CGEM·NASDAQ

$15.21

-0.85%
HealthcareMedical - Pharmaceuticals

Cullinan Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the developing of oncology and immuno-oncology therapies. Its pipeline includes CLN-978, CLN-619, Zipalertinib CLN-081/TAS6417, CLN-049, and CLN-617. The company was founded by Patrick A. Baeuerle on September 15, 2016 and is headquartered in Cambridge, MA.

At a Glance

Live Snapshot
Market Cap$934.78M
EPS-3.7200
P/E Ratio-4.09
Earnings Date08/06/2026

cgem

Other Non-Current Assets

Last Annual Value

297.00K

3-Year CAGR

-14%

5-Year CAGR

-34%

10-Year CAGR

5%

Cullinan Therapeutics, Inc.

Cullinan Therapeutics, Inc. Competitors Analysis of Other Non-Current Assets

CGEM · NASDAQ
CompanyOther Non-Current Assets
CAGR 3Y
CAGR 5Y
CAGR 10Y
297.00K
-13.5%15.1%N/A 
36.50M
0.4%2.3%N/A
CBLL logo
CeriBell, Inc.
NASDAQ:CBLL
3.95M
7.1%N/AN/A
EHAB logo
Enhabit, Inc.
NYSE:EHAB
1.90M
-29.0%-39.9%N/A
3.15M
11.3%-3.1%-10.2%
53.00K
-64.8%-64.7%N/A
389.00K
-53.5%-33.2%N/A
97.49M
-11.3%-7.2%N/A
Cullinan Therapeutics, Inc.

Cullinan Therapeutics, Inc. Fair Value Envelope

CGEM · NASDAQ

Our analysis suggests that CGEM has a fair value of HIDDEN per share in the Base Case projection. With shares currently trading at $15.21, this represents a potential HIDDEN relative to our calculated worth for Cullinan Therapeutics, Inc..

Intrinsic Value
Current Price: $15.21